Context: Increased production of antiangiogenic factors soluble endoglin (sEng) and soluble fmslike tyrosine kinase receptor-1 (sFlt-1) by the placenta contributes to the pathophysiology in preeclampsia (PE).
P reeclampsia (PE) is a maternal hypertensive disorder with unknown etiology during human pregnancy. Recent studies by Levine et al. (1, 2) revealed significantly higher maternal circulating levels of soluble vascular endothelial growth factor (VEGF) receptor-1 or soluble fms-like tyrosine kinase receptor-1 (sFlt-1) and soluble endoglin (sEng) in women complicated by PE than in women with normal pregnancies. In contrast, maternal circulating levels of free placental growth factor (PlGF) are significantly lower in women with PE. The elevated sFlt-1 and sEng levels were found to increase for several weeks in pregnant women who subsequently developed PE during their pregnancy. These findings indicate that increased maternal levels of sFlt-1 and sEng can be detectable in pregnant women before the onset of PE (1, 2) . Enhanced fms-like tyrosine kinase receptor-1 (Flt-1) expression was found in the placental tissues from PE (3) . A study by Maynard et al. (3) showed that administration of sFlt-1 adenovirus to pregnant rats could induce hypertension and glomerular endotheliosis, which mimics the maternal symptoms and pathological changes in the kidney in patients with PE. A subsequent study from the same group further noticed that endoglin (Eng), a cell surface receptor for TGF␤1, exerts a similar biological effect as sFlt-1 and may contribute to the pathogenesis in this pregnancy disorder (4) .
Both sFlt-1 and sEng have antiangiogenic effects, and are considered endogenous antiangiogenic factors in humans. sFlt-1 binds to VEGF and PlGF (5) , and blocks their angiogenic actions to vascular tissues. Eng is expressed in vascular endothelial cells and placental trophoblasts. Its function may be involved in vascular activity and homeostasis (6) . sEng could impair binding of TGF␤1 to its receptor on cell surface, thus leading to dysregulation of TGF␤1 signaling with effects on activation of endothelial nitric oxide synthase and vasodilation. PlGF belongs to the VEGF family and plays an important role in enhancing VEGFdriven angiogenesis. In contrast, loss of PlGF impairs angiogenesis, wound healing, and inflammatory responses (7, 8) .
Placentas produce sFlt-1, sEng, and PlGF. Excess amounts of sFlt-1 and sEng derived from the placenta may offset VEGF, PlGF, and TGF␤1 bioactivities, impair maternal vascular endothelial function, and induce glomerular endotheliosis in PE (3, 4) . The harmful effects produced by sEng and sFlt-1 are believed to be a major component in the pathogenesis of PE (1-3). Although it is considered that the placenta trophoblasts might be the major source of sEng, sFlt-1, and PlGF during pregnancy and abnormal placental function may lead to an increase in sFlt-1 and sEng releases during PE, trophoblast productions of sEng, sFlt-1, and PlGF in normal and preeclamptic placentas have never been simultaneously studied; neither have hypoxic effects on trophoblast sEng production. To investigate this we isolated trophoblasts from placentas delivered by normal and preeclamptic pregnant women. Isolated trophoblasts were cultured under regular (21% O 2 ) and lowered (2% O 2 ) oxygen conditions. Productions of sEng, sFlt-1, and PlGF were determined. We further examined Eng, Flt-1, and PlGF expressions by immunostaining of villous tissue sections and by Western blot analysis. Protein samples were also treated with glycosidase to determine whether glycosylated proteins for sEng, sFlt-1, or PlGF were present in the placenta.
Patients and Methods

Patient information
A total of 30 placentas, 16 from normal and 14 from PE, was used in this study. Normal pregnancy is defined as a pregnancy in which the mother had normal blood pressure (Յ 140/90 mm Hg) with the absence of medical and obstetrical complications. The definition for PE follows the guideline of National Institutes of Health publication No. 00-3029 (9) . PE is defined as maternal systolic blood pressure higher than or equal to 140 mm Hg and/or diastolic blood pressure higher than or equal to 90 mm Hg on two occasions, separated by 6 h, and proteinuria more than 300 mg in a 24-h period after 20-wk gestation. PE is considered severe if one or more of the following criteria is present: maternal blood pressure higher than or equal to 160/110 mm Hg on two separate readings at least 6 h apart; proteinuria more than 2ϩ by dipstick or more than 2 g/24 h; visual disturbances; pulmonary edema; epigastric or right upper quadrant pain; impaired liver function; thrombocytopenia; or fetal growth restriction. This study was performed at Louisiana State University Health Sciences Center in Shreveport and approved by the institutional review board for Human Research at Louisiana State University Health Sciences Center in Shreveport, LA. In the PE group, all placentas were from pregnant women who were clinically diagnosed with severe PE. None of the study subjects had signs of infection. Smokers were excluded.
Trophoblast cell isolation and culture
Trophoblast cells were isolated from freshly delivered placentas as previously described (10, 11) . Briefly, dissected villous tissue excluding chorionic and basal plates was digested with Dispase (Collaborative Biomedical Products, Becton Dickinson, Bedford, MA). Isolated trophoblast cells were purified by Percoll density gradient (Sigma-Aldrich, St. Louis, MO) centrifugation. Percoll gradients were made from 45-15% Percoll (vol/vol) in 5% steps of 5.0 ml each. Trophoblasts were recovered in the density of the gradient between 1.048 and 1.062 g/ml. To eliminate contaminated red blood cells, isolated trophoblasts were incubated with lysis buffer containing 155 mM NH 4 Cl, 10 mM KHCO 3 , and 0.14 mM EDTA (pH 7.2) on ice for 3-5 min. Cell viability was examined by trypan blue exclusion. The viability of the cells was over 95%.
Isolated trophoblast cells were placed in six-well plates with a density of 5 ϫ 10 6 cells per well in 4 ml DMEM (Sigma Chemical Inc., St. Louis, MO) supplemented with 2% fetal bovine serum. Two plates were prepared from each trophoblast isolation as previously described (11, 12) . After overnight culture under regular culture conditions (5% CO 2 in air; 21% O 2 ) to equilibrate the cultures, one plate was continued in the regular culture condition, and one plate was placed in a portable air chamber (Billups-Rothenberg, Del Mar, CA) for lowered oxygen culture, in which the chamber was filled with mixed air of 2% O 2 , 5% CO 2 balanced with 93% N 2 . The chamber was flushed daily with the mixed air for 2 min at 10 liter/min. The "lowered O 2 " condition represents a range of ambient O 2 of 2% Ϯ 0.01. The chamber was housed in an incubator to maintain 37 C temperature. All cells were cultured in duplicate for 48 h. At the end of incubation, culture medium was collected and centrifuged. The supernatant was used for measuring sEng, sFlt-1, and PlGF. Trophoblast cells were lysed with sodium hydroxide, and total cellular protein concentration per well was measured by Bio-Rad Bradford assay (Bio-Rad Laboratories, Hercules, CA). BSA was used to generate a standard curve. The protein concentration was used to calculate sEng, sFlt-1, and PlGF productions. Data are expressed as per microgram protein.
ELISA measurements for sEng, sFlt-1, and PlGF
Trophoblast productions of sEng, sFlt-1, and PlGF were measured by ELISA. The ELISA kits for sEng (CD105), sFlt-1, and PlGF were purchased from R&D Systems, Inc. (Minneapolis, MN). The range of standard curve for sEng was 15.6 -4000 pg/ml. The range of standard curve for sFlt-1 was 31.2-2000 pg/ml. The range of standard curve for PlGF was 15.6 -1000 pg/ml. Plates were read at 450 nm by an autoplate reader (Molecular Devices, Sunnyvale, CA). For each assay, all samples were assayed in duplicate in the same plate. Within-assay variation was less than 5% for each assay.
Immunohistochemical staining
Fresh villous tissues were fixed with 10% formalin. Tissue sections (4 m) were stained with monoclonal antihuman Eng (CD105), Flt-1, and PlGF. Antibody for CD105 (BD33551A2) was purchased from BD PharMingen (San Diego, CA), Flt-1 from Abcam Inc. (Cambridge, MA), and PlGF from Santa Cruz Biotechnology, Inc. (San Diego, CA). Biotinylated secondary antibodies and ABC staining systems from Santa Cruz Biotechnology were used following the manufacturer's instructions. Stained slides were counterstained with Gill's formulation hematoxylin. Tissue sections stained with secondary antibody only were used as a negative control. For each target staining, all slides (seven normal and five PE) were processed at the same time. Stained tissue slides were reviewed by Olympus microscopy (Olympus IX71; Olympus America, Inc., Melville, NY), and images were captured by a digital camera and recorded into a microscopy linked personal computer. Immunohisto-chemical staining studies were mainly used for detecting localization of target molecules in the placental villous tissue.
Protein expression
Snap-frozen tissues were homogenized, and placental tissue protein expressions for Eng, Flt-1, and PlGF were determined by Western blot analysis. Briefly, total tissue protein 50 g each sample was subject for electrophoresis (Mini-cell protein-3 gel running system; Bio-Rad) and then transferred to nitrocellulose membrane. The membranes were probed with a primary mAb against Eng, Flt-1, PlGF, or polyclonal antibody actin (Sigma-Aldrich). The bound antibodies were visualized with an enhanced chemiluminescent detection kit (Amersham Corp., Arlington Heights, IL). Nitrocellulose membranes were stripped and blocked before they were probed with a different antibody.
Protein deglycosylation
Deglycosylation was performed using N-glycosidase F. Briefly, an aliquot of 100 g total protein per sample was incubated with 1.0 U N-glycosidase F (Calbiochem, San Diego, CA) at 37 C for 48 h. One unit glycosidase catalyzes the release of N-linked oligosaccharides from 1.0 nmol denatured ribonuclease B per minute at 37 C (pH 7.5). Cleavaged protein was monitored by SDS-PAGE and probed with antibody against Eng, Flt-1, or PlGF.
Statistical analysis
Data are presented as mean Ϯ SE. The Student t test or paired t test was used for statistical analysis by StatView computer software (SAS Institute Inc., Cary, NC). A probability level of P Ͻ 0.05 was considered statistically significant.
Results
Trophoblast cell productions of sEng, sFlt-1, and PlGF
The productions of sEng, sFlt-1, and PlGF by trophoblasts that were cultured under 21% O 2 and 2% O 2 conditions are shown in Fig. 1 . Under the 21% O 2 culture condition, trophoblast cells from preeclamptic placentas produced significantly more sEng, sFlt-1, and PlGF than trophoblast cells from normal placentas: sEng 1.726 Ϯ 0.272 vs. 1.123 Ϯ 0.194 pg/g protein, P Ͻ 0.05; sFlt-1 138 Ϯ 26 vs. 77 Ϯ 9 pg/g protein, P Ͻ 0.05; and PlGF 0.084 Ϯ 0.025 vs. 0.021 Ϯ 0.004 pg/g protein, P Ͻ 0.05, respectively. There were no differences for sEng and sFlt-1 production by normal trophoblast cells cultured between 21% O 2 and 2% O 2 conditions: sEng 1.123 Ϯ 0.194 vs. 1.139 Ϯ 0.194 pg/g; and sFlt-1 77 Ϯ 9 vs. 62 Ϯ 12 pg/g. In contrast, trophoblast cells from preeclamptic placentas produced more sEng when they were cultured under 2% O 2 compared with 21% O 2 (2.359 Ϯ 0.434 vs. 1.726 Ϯ 0.272 pg/g; P Ͻ 0.05). Although sFlt-1 productions were increased by preeclamptic trophoblast cells when they were cultured with 2% O 2 , the value was not statistically significant (170 Ϯ 36 vs. 138 Ϯ 26 pg/g; P ϭ 0.315). For PlGF, trophoblasts from both normal and preeclamptic placentas produced significantly less PlGF when cultured under 2% O 2 condition: normal 0.008 Ϯ 0.002 vs. 0.021 Ϯ 0.004; and PE 0.021 Ϯ 0.001 vs. 0.084 Ϯ 0.025 pg/g, P Ͻ 0.05, respectively.
Immunostaining of Eng, Flt-1, and PlGF
Tissue sections from 12 placentas (seven normal and five PE) were immunostained for Eng, Flt-1, and PlGF. Our results showed that: 1) positive staining for Eng, Flt-1, and PlGF was mainly localized in the syncytiotrophoblast layer; and 2) enhanced staining for Eng and Flt-1, but reduced staining for PlGF, was observed in preeclamptic tissue sections compared with normal tissue sections. Examples of immunostaining results from one normal and one preeclamptic placenta are shown in Fig. 2 (A and D, Eng; B and E, Flt-1; and C and F, PlGF). Both placentas were delivered at 38 wk.
Placental tissue protein expressions for Eng, Flt-1, and PlGF
Placental tissue protein expressions for Eng, Flt-1, and PlGF are shown in Fig. 3 . Total protein samples were run on SDS-PAGE under reducing conditions. Our results showed different patterns for Eng, Flt-1, and PlGF expressions between normal and preeclamptic placentas. Eng and Flt-1 protein expressions were up-regulated in preeclamptic tissue samples, whereas PlGF protein expressions were down-regulated in preeclamptic tissue samples. For Eng expression (Fig. 3A) , there are two major bands in the preeclamptic samples with one approximate molecular mass of 65 kD and one approximate of 90 kD, whereas, only a 65-kD band is shown in the normal samples. For Flt-1 expression (Fig. 3B) , an intense band with an approximate molecular mass of 65-72 kD is shown in both normal and preeclamptic samples, whereas in preeclamptic tissues, there are intense and diffused bands with molecular masses of 100 -150 kD and a band with a lower molecular mass of approximately 40 -45 kD. In contrast, a week band with an approximate molecular mass of 140 -150 kD is shown in the normal tissue samples. For PlGF expression (Fig. 3C) , one band shows up with an approximate molecular mass of 55 kD in normal and PE placental tissue samples. Whereas in the PE samples, an additional lower band with a molecular mass of approximately 28 kD is observed.
sEng and sFlt-1 expression
Because of the different patterns of Eng, Flt-1, and PlGF protein expressions detected between normal and preeclamptic placental tissues (Fig. 3) , we further determined the molecular mass of sEng, sFlt-1, and PlGF released by trophoblast cells. Trophoblast culture media were run on SDS-PAGE under reducing conditions. An aliquot of 10 g protein per medium sample was loaded per lane. As shown in Fig. 4 , only the 65-kD band was detected for Eng in both normal and preeclamptic trophoblast culture media (Fig. 4B, upper  panel) , compared with the tissue protein expressions (Fig. 4A, upper  panel) . These results suggest that the 65-kD molecular mass is probably sEng. For Flt-1 expression, a diffused band with a molecular mass of 110 -150 kD is shown in both normal and preeclamptic trophoblast medium samples, but the diffused band is more intense in the preeclamptic trophoblast medium samples (Fig. 4B, lower  panel) . The medium Flt-1 expression pattern suggests that the molecular mass of approximately 110 -150 kD is probably sFlt-1. Medium PlGF protein expression was undetectable by Western blot (data not shown).
Glycosylated Eng and Flt-1 expressions
Eng, Flt-1, and PlGF have putative N-glycosylation sites, which may account for the different molecular masses of their protein size revealed by the Western blot (Fig. 3) . Glycosylations are known to occur in different cell compartments, including cell membrane, cytoplasm, and nucleus. To explore further whether glycosylated Eng, Flt-1, and PlGF are present in the placental tissue, an aliquot of total tissue protein from two preeclamptic placentas was digested with N-glycosidase F, and then deglycosylated samples and undeglycosylated controls were separated by SDS-PAGE under reducing conditions and probed with Eng, Flt-1, or PlGF antibody, respectively. As shown in Fig. 4C (upper panel) for Eng expression, after glycosidase digestion the 90-kD band disappeared, and two new bands show up, one at approximately 75-78 kD, and one at approximately 28 kD. These results imply that the 90-kD molecular mass is probably a glycosylated form for Eng, and more glycosylated Eng is present in placental tissues from PE (Fig. 4A, upper panel) . However, it seems that the putative sEng (ϳ65 kD) released by trophoblasts is unglycosylated (Fig. 4B, upper panel) . For Flt-1 expression, after glycosidase digestion, three new bands show up: one around 90 -120 kD, one at approximately 55 kD, and one at approximately 28 kD (Fig. 4C, lower panel) . These results suggest that dominant glycosylated sFlt-1 is probably present in the preeclamptic placental tissue (Fig. 4A, lower panel) . In contrast to Eng, trophoblasts are more likely able to release glycosylated sFlt-1 (Fig. 4B, lower panel) . No band was detected when the blots were probed with antibody against PlGF (data not shown).
Discussion
In this study we determined sEng, sFlt-1, and PlGF productions by trophoblasts from normal and preeclamptic placentas. We found that placental trophoblasts from preeclamptic pregnancies produced significantly more sEng, sFlt-1, and PlGF than normal trophoblasts when cells were incubated under regular culture condition (20% O 2 ). We further noticed increased sEng and sFlt-1 productions by preeclamptic trophoblasts, but not by normal trophoblasts, when they were cultured under lowered oxygen condition (2% O 2 ). PlGF production was significantly reduced by trophoblasts from both normal and preeclamptic placentas when they were cultured under lowered oxygen condition. The different productions of sEng, sFlt-1, and PlGF by normal and preeclamptic trophoblasts cultured under regular and lowered oxygen conditions suggest that:
1. Trophoblast cells from normal placentas might be able to compensate or be more resistant to lowered oxygen stimulation than the cells from preeclamptic placentas. In other words, the lack of endogenous protective factors such as heme oxygenase-1 (13), as well as antioxidant superoxide dismutase and glutathione peroxidase in trophoblasts may contribute to the increased sEng and sFlt-1 productions by preeclamptic placentas (10, 14) .
2. Compared with sEng and sFlt-1 productions, PlGF production may be the most sensitive one being affected by lowered oxygen environment.
To determine whether increased Eng and Flt-1 and decreased PlGF immunoreactivities are present in preeclamptic placentas, villous tissue sections were immunostained with antibodies against Eng, Flt-1, and PlGF. Our results showed that positive stainings for Eng, Flt-1, and PlGF were mainly localized in the syncytiotrophoblast layer of the placenta. Compared with normal placentas, tissue sections from preeclamptic placentas showed intense immunostaining of Eng and Flt-1, but reduced immunostaining of PlGF, in the syncytiotrophoblasts of preeclamptic placentas. The Western blot data of increased Eng and Flt-1, but decreased PlGF, expressions in preeclamptic placentas are consistent with the immunostaining observations. These results support the concept that aberrant angiogenic and antiangiogenic factor activities occur in preeclamptic placentas. One discrepancy we observed in this study is the result of a relatively more PlGF production in preeclamptic trophoblasts than in normal trophoblasts when cultured under 21% O 2 condition in contrast to reduced PlGF immunostaining in the villous tissue from preeclamptic placentas. The reason for this discrepancy in PlGF production between cultured trophoblasts and tissue expression from preeclamptic placentas is not known. However, a similar phenomenon had been observed for vasodilator prostacyclin production (15) , in which more prostacyclin was produced by isolated trophoblasts from preeclamptic than trophoblasts from normal placentas. In contrast, whole villous tissue from preeclamptic placentas produced less prostacyclin than that from normal placentas (16) . It is possible that the loss of tissue integrity control in isolated trophoblasts might account for the dissociated phenomenon in PlGF production by trophoblasts and its expression in whole villous tissue.
Both Flt-1 and Eng genes contain hypoxia-inducible factor-1 binding sites. In the present study, we did not examine the signaling pathway regulation of Eng and Flt-1 in trophoblasts because previous published work demonstrated that hypoxia-inducible factor-1␣ expression was increased in cells cultured under lowered oxygen condition (17), a key regulator of upregulation of Flt-1 and Eng expression.
One of the most significant findings of the present study is the different pattern of total tissue protein expressions for Eng, Flt-1, and PlGF between normal and preeclamptic placentas. Eng is a type I integral membrane protein with a molecular size of approximately 68 kD (18) . Our Western blot data revealed two bands for Eng, one at approximately 65 kD and one at 90 kD, which are consistent with the results reported by Venkatesha et al. (4) , which show that Eng protein exists as a 90-kD "full length" and a 65-kD soluble form in the preeclamptic placenta when the samples were determined by SDS-PAGE under reducing conditions. Soluble and truncated forms of human Eng are present as a disulfide-linked dimer (19) . Mature and monomer sFlt-1 is an approximate 70-kD protein (20) . The higher molecular mass bands of Eng and Flt-1 in preeclamptic tissue samples revealed by Western blot analysis (Fig. 3) implicate that Eng and Flt-1 may very likely exist as dimer, polymer, and/or complex formation, especially in the preeclamptic placentas. By examining medium protein expression, we confirmed that sEng released by trophoblasts is a 65-kD protein under reducing conditions. These results agree with the results reported by Raab et al. (19) . In contrast, sFlt-1 released by trophoblasts may exist as a dimer or a complex form. The latter one may include glycosylated sFlt-1 or ligand/receptor complex formed by binding of VEGF/ PlGF to Flt-1 or sFlt-1. This notion is supported by our Western blot data shown in Fig. 4 , and the ligand binding and receptor dimerization study of Flt-1 by Barleon et al. (20) . The mature PlGF is about 28 -32 kD and usually exists in a homodimeric structure (5) . It seems that PlGF is present either as monomer or dimer in preeclamptic placentas, whereas only dimerized PlGF is present in the normal placental tissue.
Another important finding of the present study is that more glycosylated Eng and Flt-1 are present in the preeclamptic placentas (Fig. 4) . Studies have shown that the extracellular peptide sequence for Flt-1 has 11 putative glycosylation sites (20) , and Eng has four putative glycosylation sites (18) . Theoretically, PlGF has four putative glycosylation sites (5) . Unfortunately, we were unable to detect glycosylated PlGF in preeclamptic placentas. It is well known that a glycosylated protein has different physical and biochemical properties from its deglycosylated format (21) . A glycosylated or deglycosylated protein may lead to functional diversities. For example, deglycosylated human chorionic gonadotropin interacts with a different domain of the receptor compared with its native hormone (22) . Glycoprotein could attribute to the heterogeneity of its constitute oligosaccharides (23) . In the present study, glycosylated protein may account for the broadened bands observed for sFlt-1 expression in preeclamptic placental tissues detected by Western blot analysis. The ubiquity of glycosylation is well established, and it is quite common with secreted proteins. In blood serum, almost all proteins are glycosylated (21) . Interestingly, by examining sEng and sFlt-1 expressions in the trophoblast culture medium, we found that placental trophoblasts produce/release glycosylated sFlt-1, but unglycosylated sEng, in vitro. It seems that trophoblast cells from preeclamptic placentas produce more glycosylated sFlt-1 than that from normal placentas. At the present time, we do not know whether our in vitro observations reflect the changes that might occur in vivo in PE, and what the properties are between the glycosylated sFlt-1 and sEng from their deglycosylated ones. Further study of their functional differences may provide insight regarding their antiangiogenic actions and their role in PE.
